abs382.txt	background		the	purpose	of	the	current	study	was	to	determine	quality	of	life	andtumor	control	from	a	prospective	phase	2	clinical	trial	evaluating	deintensifiedchemoradiotherapy	for	favorable	risk		human	papillomavirus	(hpv)-associatedoropharyngeal	squamous	cell	carcinoma	methods		patients	with	t0-t3		n0-n2c		m0		p16-positive	disease	and	a	minimalsmoking	history	were	treated	with	60	grays	of	intensity-modulated	radiotherapywith	concurrent	weekly	intravenous	cisplatin	(30	mg/m2	)		the	primary	studyendpoint	was	the	pathologic	complete	response	rate	based	on	biopsy	of	the	primarysite	and	dissection	of	pretreatment	positive	lymph	node	regions		the	pathologiccomplete	response	rate	as	previously	reported	was	86%		herein		the	authors	reportsecondary	endpoint	measures	of	local	control		regional	control		cause-specificsurvival		distant	metastasis-free	survival		and	overall	survival		andpatient-reported	outcomes	(european	organization	for	research	and	treatment	ofcancer	[eortc]	quality	of	life	questionnaire	[eortc	qlq-c30]	and	thepatient-reported	outcomes	version	of	common	terminology	criteria	for	adverseevents	[pro-ctcae])	results		a	total	of	44	patients	enrolled	with	a	median	follow-up	of	36	months(88%	with	≥2	years)		the	3-year	local	control		regional	control		cause-specificsurvival		distant	metastasis-free	survival		and	overall	survival	rates	were	100%	100%		100%		100%		and	95%		respectively		the	mean	before	and	3-year	after	eortcqol	scores	were		global		80	of	78		swallowing		11	of	11		dry	mouth		16	of	41		andsticky	saliva		6	of	29		the	mean	before	and	3-year	after	pro-ctcae	scores	were	swallowing		0	4	of	0	7		and	dry	mouth		0	4	of	1	4		approximately	39%	of	patientsrequired	a	feeding	tube	(median	duration		15	weeks		none	were	permanent)		therewere	no	≥grade	3	late	adverse	events	reported	conclusions		for	patients	with	favorable-risk	human	papillomavirus-associatedoropharyngeal	squamous	cell	carcinoma		a	substantially	decreased	intensity	oftherapy	with	60	grays	of	intensity-modulated	radiotherapy	and	weekly	low-dosecisplatin	produced	better	preservation	of	quality	of	life	compared	with	standardtherapies	while	maintaining	excellent	3-year	tumor	control	and	survival		cancer2018	124	2347-54		©	2018	american	cancer	society	
